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Allergic encephalomyelitis may be induced in rats and several other species 
of laboratory animals by single or repeated injections of mammalian brain or 
spinal  cord  emulsified  in  Freund's  adjuvant  (1-9).  Clinical  signs  of  central 
nervous system disease are displayed by animals 2  to 3 weeks after injection. 
The disease is identified pathologically by the presence of characteristic focal 
areas of vascular and perivascular inflammation confined to the brain, spinal 
cord, and their meningeal coverings. In some species of animals, these lesions 
may be accompanied by perivascular demyelination. For convenience, allergic 
encephalomyelitis will be referred to here as AE. 
Numerous studies of AE have suggested that  this disease  has an immunological 
mechanism. Paterson (10) and Waksman (11) have recently reviewed many of these 
studies.  Direct evidence for an immunological  mechanism, however, by transferring 
AE to animals by means of serum or cells has not been reported. Since 1947, attempts 
by several investigators  (3-5,  12-16)  to accomplish transfer in  this manner,  using 
rats,  guinea pigs, and  monkeys, have failed.  Chase  (17) has recently summarized 
the results of these, as well as previously undescribed,  AE transfer attempts. Lipton 
and Freund  (14) in  1953 did succeed  in transferring AE in rats using the technique 
of parabiosis. Their experiment has provided the only evidence  of the feasibility of 
AE transfer by serum or cells. 
This paper describes  the transfer of AE in rats by injection of lymph node  cells 
from actively sensitized  donors  into  recipients pretreated  neonatally  with  normal 
rat spleen  cells. The design  of this study was based on  the concept that  extended 
survival of donor cells in recipients might be a  key factor in transfer. In past work 
employing genetically dissimilar  donors and recipients,  transferred cells would  not 
be expected to survive and function for very long because they would  be rejected 
immunologically by the recipients (18). From the studies of Woodruff and his associates 
(19-21),  confirmed  by Egdahl et al. (22), it was known that rats injected neonatally 
with  rat spleen  cells may acquire immunological  tolerance to skin  homografts and 
later be unable to reject skin transplants derived from the spleen cell donors. 
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It  seemed likely that  cellular transfer of  allergic encephalomyelitis might 
well be accomplished using recipient rats pretreated in this fashion.  Such pre- 
treated recipients would be expected to have some tolerance of sensitized donor 
lymph node cells and, consequently, permit these cells to survive and function 
longer after transfer.  In this more favorable environment, the surviving trans- 
ferred  cells  themselves or  antibodies continually elaborated by them  would 
have a better opportunity to react with antigen(s) in the brain and spinal cord 
of the recipients. 
Experimental Procedures  and Methods 
Design of Transfer Experiments.--As shown diagrammatically in Text-Fig. 1, newborn rats 
were pretreated  with pooled, normal spleen cells from splenectomized adult donor rats. Five 
to 6 weeks later, the donor rats were injected with guinea pig spinal cord in adjuvant. Lymph 
node cells were collected from the donors 7 or 12 days later. The lymph node cells were pooled, 
washed, and injected intravenously into the pretreated,  and now adult,  recipient rats. The 
recipients were observed for 6 to 8 days after lymph node cell transfer, then sacrificed, and 
their brains and spinal cords examined microscopically for neurological lesions. All recipient 
rats were deliberately sacrificed within 6, 7, or 8 days after lymph node cell transfers in order 
to minimize the possibility of lesions resulting from active sensitization to transferred spinal 
cord antigen.  Comparable lymph node cell transfers were performed using control donors 
injected with guinea pig kidney-adjuvant  and control recipients which were not pretreated 
with spleen cells. 
Rats.--CFN rats and albino rats (designated as HLH rats) were purchased from two com- 
mercial breeders,  1 respectively. Both types of rats were derived from dosed, random-bred, 
colonies of Wistar stock rats.  They were not highly inbred. Adults weighed 100 to 175 gin. 
each. Litters of rats, born in the laboratory, were obtained from pregnant females purchased 
4 to 10 days before term. Adult rats were housed in large wire cages. Neonatal rats were kept 
with their mothers in metal boxes containing  wood shavings until 3 to 4 weeks old at which 
time they were weaned and then housed in wire cages. Food pellets and fresh tap water were 
provided daily.  2 Only females were used as donors in order to avoid sex-linked tissue incom- 
patibility reported to occur in inbred strains of mice by Eichwald and Silmser (23), Adler 
(24), and other workers (25, 26)--an incompatibility postulated to occur owing to antigens 
determined by a gene, or genes, associated with the Y chromosome of males. Both male and 
female rats were used as recipients. 
Spt~neaomy.---Groups of 4 adult rats each were etherized, abdominal hair removed with 
electric clippers, and exposed skin swabbed with tincture of merthiolate  (1:1000) and then 
70 per cent ethyl alcohol. Using aseptic technique, the spleen was delivered through an incision 
in the left upper abdominal quadrant and the spleen stump ligated with 2 silk sutures. The 
entire spleen was cut free with scissors and removed. The ligated stump was returned to the 
abdomen and incised muscle and skin were closed with interrupted silk sutures. 
At the outset of this work, from 50 to 75 per cent of HLH rats displayed typical features 
of Haemobartondla  muris infection about 6 days after splenectomy (27). These rats lost weight, 
appeared weak, and exhibited clinical signs of a severe hemolytic anemia (progressive pallor 
and hemoglobinuria) confirmed by hematocrit values and blood smears. Giemsa-stained blood 
a CFN rats obtained from Carworth Farms, New City, New York; HLH rats obtained from 
Hemlock Hollow Farms, Paterson, New Jersey. 
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smears from  15 moribund  rats were examined microscopically and  1 to 20 per cent of the 
erythrocytes in a given oil immersion field found to contain i to 15 minute coccobacillary bodies 
indistinguishable from H. mutis.  Neopeptone broth and thioglycolate media inoculated with 
blood from ill rats and incubated at 37°C. showed no evidence of bacterial growth over a period 
of 10 days. It was found that addition of approximately 20 mg. of aureomycin  3 to each 100 
ml. of drinking water offered daily to HLH rats for 2 weeks after splenectomy, and periodically 
thereafter, suppressed dinical illness.  Rats receiving this medicated water gained weight, ap- 
peared healthy in all respects, and could be used  successfuly as donors for cell transfers. In 
contrast to HLH rats,  the CFN rats, known  to  be "specific pathogen free," remained well 
after  total  splenectomy and  examination  of  blood  smears  made  periodically revealed no 
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T~xx-FIo. 1. Design of allergic encephalomyelitis transfer study. 
erythrocyte parasitism.  It should be stressed that there is no evidence that H. mttris plays 
any role in the pathogenesis of AE in rats. AE may be induced actively in both HLH and 
CFN rats (see Table I) and comparable results were obtained in the transfer studies described 
here using either type of rat. 
Spleen Cell Suspensions and Pretreatment of Rats.---One to 4 donor rat spleens,  immediately 
after removal, were placed in chilled Hanks balanced salt solution (HBSS)4 containing sodium 
bicarbonate, and cut into 2 or 3 pieces.  The cells were expressed and isolated by repeatedly 
squeezing the spleen segments with  thumb  forceps and  passing the spleen cell suspension 
through a 25 gauge needle. The cells in HBSS were pooled, transferred to a graduated conical 
tube, and centrifuged at 145 G  for 5 minutes at 4°C. The washed cells were promptly rcsus- 
pended in a sufficient volume of fresh, chilled, HBSS to give approximately the desired cell 
concentration. 
3 Chlortetracycline HC1, American Cyanamid Co., New York. 
4 Microbiological Associates, Bethesda, Maryland. 122  TRANS]?ER OF  ALLERGIC  ENCEPHALOMYELITIS 
Twenty-four litters of HLH and CFN neonatal rats were pretreated with different spleen 
cell suspensions.  One to 8 rats in a litter were injected intraperitoneally with 0.3 to 0.5 ml. 
of each cell suspension.  Each rat received from 17 to 49 million viable nucleated spleen cells as 
determined by eosin-Y vital staining (28) and hemocytometer counts of aliquots of injected 
cell suspensions.  Eighteen litters were injected 1 to 3 days after birth. The remaining 6 litters 
were injected 4, 6  (2 litters),  10, and  12  (2 litters) days after birth, respectively. Beginning 
about 10 days after injection, a variable proportion of rats in different litters showed clinical 
signs of disease.  This disease was characterized clinically by failure to gain weight, sparse 
growth of hair particularly over the face and distal portions of extremities, roughened skin, 
progressive weakness, and variable pallor. Death occurred usually 14 to 22 days after injection 
of spleen cells. The disease was observed in both HLH and CFN rats and was related directly 
to the number of viable spleen cells injected neonatally. Brains of 9 rats injected with spleen 
cells when I  day old and dying of this disease 18 to 25 days later showed neither gross nor 
microscopic histological abnormalities.  It would appear that this disorder is similar to that 
known as "runt syndrome" described  by Billingham and Brent (29) and  other workers (30, 
22)  in mice, chickens,  and  rats,  injected emhryonically or neonatally with foreign, living, 
immunologically competent cells. Those pretreated rats appearing well when 5 to 6 weeks old 
and presumed to have acquired immunological tolerance to donor cells because of prior neo- 
natal treatment were used as recipients for lymph node cell transfers. 
Tiss~-Adj~ant Inocul~  and Injeaion of Rats.--Spinal  cord and kidneys were removed 
aseptically from Hartley guinea pigs  5 weighing 450 to 600 gm. each and stored at -25°C. for 
1 to 6 days.  Spinal cord was used promptly without  freezing on one occasion and in two 
instances after storage at -  25°C. for 25 and 29 days. Weighed portions of thawed tissues were 
homogenized in  distilled water  containing 0.25  per cent phenol  using a  TenBroeck  tissue 
grinder. All homogenates contained 33 per cent tissue (wet weight). Complete adjuvant was 
prepared  as described by Freund  (31).  Heat-killed, lyophilized, Mycobaao~um  tuberculosis 
(strain H37Rv) 6 cells were suspended in 9 parts paraitin oiF and ! part emulsifying agent  8 in 
a mortar by stirring with a pestle. Each final milliliter of complete adjuvant contained 4 rag. 
of M. tuberc~dosis. Adjuvant preparations  were autoclaved for 20 minutes at  120°C.  and  a 
pressure of 20 pounds and then stored at 4°C. Tissue homogenates were emulsified in equal 
volumes of adjuvant in a mortar by stirring with a pestle. Rats were etherized lightly, hair 
over the back removed by electric clippers, and the exposed  skin swabbed with 70 per cent 
ethyl  alcohol.  Each  animal was injected intracutaneously  with 0.I  ml.  of tissue-adjuvant 
emulsion in each of 6 sites on the upper one-third of the back and 1 site on the anterior surface 
of the neck. Each rat received approximately 115 mg of spinal cord or kidney (wet weight). 
Donor Lymph Node Cell S~pensions.--Donor  rats were sacrificed 7 or  12 days after in- 
jection of spinal cord or kidney in adjuvant.  Using aseptic  technique throughout,  3  to  5 
anterior cervical and 2 to 3 axillary lymph nodes were removed from each of 1 to 4 donor rats. 
The nodes were immediately pooled in chilled HBSS, trimmed, and cut into small fragments 
with scissors.  The fragments were then pressed  through  mesh screening ("cytosieve",  9 de- 
scribed by Snell (32)),  using fresh HBSS, in order to obtain suspensions  of dissociated cells. 
s Guinea pigs of Hartley strain  obtained from Tumblebrook  Farms,  Chestertown,  New 
York. 
s The strain of Mycoba~terium tuberculosis was grown on medium prepared as described by 
Youmans, G. P., A method for the determination of the culture cycle and the growth rate of 
virulent human type tubercle bacilli, J. Baa., 1946, 61,  703. 
Light paraffin oil, called bayol-F, obtained from Esso Standard Oil Co., New York. 
8 Arlacel-A kindly provided by Atlas Powder Co., Wilmington. 
9 Cytosieves obtained from Macalaster Bicknell Co., Cambridge, Massachusetts. P.  Y.  PATERSON  123 
The ceils were then washed at 4°C. using 1 or 2 cycles of centrifugation at 145 G for 5 minutes 
and  resuspended in fresh HBSS to give approximately the desired concentration of lymph 
node cells to be transferred. Aliquots of these cell suspensions were examined microscopically 
and were found to consist mainly of isolated cells with minimal clumping and little debris. As 
many as 36 lymph nodes from 4 donors could be removed and processed as described within 1 
hour. 
Transfer o.f Lymph Node Cdis.--Recipient  rats were etherized lightly, their tails warmed 
for 1 minute in tap water heated to 50°C. and injected in the lateral tail veins with 0.5 to 1.0 
ml. of lymph cell suspensions.  In 3 transfers of larger volumes of cells,  1.0 ml. was injected 
intravenously and 0.25  to 1.0 ml. was injected intraperitoncally. Each lymph node cell sus- 
pension was transferred  to 1 to 4 recipients. Each recipient received from 10 to 244 million 
viable nucleated lymph node cells,  based on eosin-Y vital staining (28) and hemocytometer 
counts  of aliquots of lymph node cell suspensions  transferred.  Only an occasional animal 
exhibited respiratory distress and transitory cyanosis for a  few minutes after injection. The 
recipients were observed daily for clinical ggus, sacrif~od 6, 7, or 8 days after cell transfer, and 
their brains and spinal cords removed for histological examination. 
Histological Studies.--Brains,  spinal cords, and other tissues (thyroid, heart, liver, lungs, 
spleen, kidneys, adrenals, testis, mesenteric and axillary lymph nodes) were fixed in 10 per cent 
formaldehyde in tap water.  Blocks of tissues were processed through the stage of paraffin 
embedding in an autotechnicon. Sections 5 to 10 microns thick were stained with hematoxylin 
and rosin in the usual manner. Adjacent sections of brains and spinal cords were cut at 15 to 
20 microns and stained using the luxol fast blue technique (33) for myelin studies. A minimum 
of 12 different hematoxylin and rosin stained sections of nervous tissue from each recipient 
rat were examined microscopically. These sections were cut through  the thalamus,  mesen- 
cephalon, cerebelhim-pons, medulla, and cervical-thoracic spinal cord. 
Complement Fixation  (CF)  Tests.--Blood  samples  were obtained  aseptically by cardiac 
puncture from recipients when sacrificed,  allowed to clot at 4°C. for 16 to 18 hours and sera 
collected by centrifugation. Sera were stored in sterile, cork-stoppered, glass tubes at --25°C. 
The brain antigen used in the CF tests was an ethanol extract of lyophilized normal rat brains 
prepared as previously described (2). Sheep blood in Alsever's solution, ampules of lyophilized 
guinea pig complement (C') and rabbit anti-sheep red cell immune serum were obtained from 
one commercial source?  ° Quantitative CF tests were performed  using the 50 per cent hemo- 
lytic technique as described by Kabat,  Mayer,  Osler,  and  associates  (34--37) with certain 
modifications. A colorimeter  n was used to standarize sheep red blood cell suspensions  and to 
obtain optical densities (O.D.) of supernatants from final reaction mixtures. One volume of 5 
per cent sheep red cell suspension lysed in 29 volumes of distilled water gave an O.D. of 0.342 
at a wavelength of 540 millimicrons. Final values were corrected by proportion and represented 
the number of C'H~0 of exactly I00 C'H~0 available fixed  by 0.25  ml. of  rat serum in the 
presence of appropriately diluted rat brain antigen. 
EXPERIMENTAL  RESULTS 
P aralytogenic A ctivity of Spinal Cord--Adjuvant I nocula.--Since  the majority 
of donor rats were sacrificed 7 days after injection of spinal cord adjuvant, at a 
time when they would not yet be expected to exhibit clinical signs of neurologi- 
cal  disease,  groups  of  control  rats  were  injected  with  the  same  spinal  cord 
emulsions  in  order  to  be  sure  that  the  emulsions  had  paralytogenic  activity. 
x0 Certified Blood Donor Service, New York. 
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The occurrence of AE in these control rats is shown in Table I  and is repre- 
sentative of AE induced actively in more than 150 other rats in this laboratory 
during the past 2 years. Each of the 12 inocula was paralytogenic and induced 
AE in from two-thirds to all of the H:LH or CFN rats in each group. A total of 
35  of the 43  rats  (81  per  cent)  developed AE.  Twenty-one of these  35  rats 
exhibited  ataxia  and  hindleg  weakness  or  paralysis  and  were  subsequently 
TABLE  I 
Allergic  Encephalomyelitis  (AE)  in  Control Rats Inje,  ted with Same Spinal  Cord Adjuvan  t 
Emulsions Used to Inject Donor Rats 
Rat group No.* 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
No. ofra~ 
No. of rats with 
AE lesions only  I Both clinical signs 
and AE lesions 
Occurrence of AE 
2/3t 
4/4 
3/5 
3/3 
2/3 
2/3 
3/3 
2/3 
2/2 
6/8 
3/3 
3/3 
Total.  43  14/43  21/43  35/43 
* CFN rats used for groups 1 to  and I-ILH rats used for groups 5 to 11. Group 12 con- 
sisted of 1 HLH and 2 CFN rats splenectomLzed 8 to 11 weeks previously. Rats observed 
for 21  to 26 days after injection, then  sacrificed, and  brains--spinal  cords examined for 
AE lesions. 
t Numerator, No. of rats with AE lesions; denominator, No. of rats in group. 
found to have AE lesions in their brains and spinal cords. These clinical signs 
in  16  of the  21  animals  were first  seen  12  to  15  days after injection.  Signs 
appeared initially in the other 5 rats 11, 16, 17, 18, and 19 days after injection, 
respectively. The remaining  14 animals  displayed no  clinical  signs  but  were 
found to have typical AE lesions. It should be noted that AE occurred in each 
of the splenectomized rats in group 12,  indicating that presence of the spleen 
is not essential for induction of disease. 
It can also be mentioned that neonatal pretreatment of rats with normal rat 
spleen ceils does not alter the capacity of such animals to develop AE.  Eight 
rats injected  2  to 8  days after birth  with  26 to 44 million spleen cells were P.  Y.  PATERSON  125 
injected with spinal cord adjuvant 5 to 10 weeks later. Seven of these 8 animals 
developed typical AE. 
Transfer of Lymph Node Cells to Recipient Rats Pretreated with Spleen Cells.- 
Thirteen lymph node cell transfers were carried out using donors injected with 
TABLE II 
Allergic Encepkalomyditis  (AE) in Recipient Rats after Transfer of Lymph Node Cells 
Donor rats providing lymph node cells injected with spinal cord adjuvant. Recipient rats 
pretreated neonatall r with normal spleen cells from same donor rats (see text) 
Transfer No.* 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
Total .............. 
No. of donor 
rats* 
28 
No. of  donor 
lymph node cells 
transferred  (X I0  e) 
10 
32 
32 
37 
55 
59 
61 
64 
92 
10611 
108 
I08 
156 
No. of rats 
22 
Recipient rats$ 
after I  Occurrence  of 
D~r~ ,~  AE lesions 
SaC 
1/2§ 
e  1/2 
7  1/1 
8  1/3 
8  1/1 
8  ~I~ 
7  1/I 
8  ~/1 
7  1/l 
7  0/1 
8  tI2 
8  111 
6  sis 
14/22 
* Donors in transfers 5, 8,  11 and  12 sacrificed 12 days after injection; although none of 
these 10 donors displayed clinical signs of AE, 2 of them had AE lesions. The 18 donors in the 
remaining 9  transfers were sacrificed 7 days after injection; none showed clinical signs of 
AE and only 1 of 13 examined histolo~cally had AE lesions. 
~: Recipients pretreated with from 14 to 49 million viable spleen cells when 1 to 3 days old 
except those used in transfers 5, 8 and 10 which were pretreated when 10, 12, and 6 days old, 
respectively. Lymph node cells transferred  to recipients 5 to 6 weeks after pretreatment. 
§ Numerator, No. of recipients with AE lesions; denominator, No. of recipients used in 
transfer. 
[I Injected into recipient solely by intraperitoneal route; intravenous route used in other 
transfers. 
spinal cord and recipients pretreated neonatally with spleen cells from these same 
donor rats. The results of these transfers are shown in Table II. A total of 14 of 
22 recipients were found to have AE lesions after transfer of 10 to 156 million 
viable donor lymph node cells.  The number of lesions demonstrable in each of 
these 14 positive recipients varied from a minimum of 2 to a maximum of 15. 126  TRANS]~ER  OI  r  ALLERGIC ENCEPHALOMYELITIS 
Both the number and intensity of lesions  in these recipients appeared to be 
related directly to the number of donor lymph node cells transferred. 
In the 12 successful  transfers~ lymph node cells were collected from donors 
either 7 or 12 days after injection of spinal  cord adjuvant and the donor: re- 
cipient ratios ranged from 0.5 to 3. In the single unsuccessful  transfer, No. 10, 
the recipient was injected with donor cells solely by the intraperitoneal  route 
after repeated failures to enter the tail vein. This observation may be important 
in view of the fact that all other recipients received intravenous injections of at 
least half or, in most instances,  all of the transferred  lymph node ceils. 
Clinical  neurological  signs  were observed in the 2 recipients in  transfers 5 
and 7. These animals  exhibited ataxia and hindieg weakness 4 and 5 days after 
cell transfer, respectively. These signs were still present when the animals were 
sacrificed  4  and  2  days later,  respectively.  Both animals  were subsequently 
found to have intense neurological  lesions.  None of the other  recipients dis- 
played clinical signs. 
The central nervous system (CNS) lesions in the 14 recipients consisted of 
discrete  collections  of inflammatory  cells  within  the  walls and  perivascular 
spaces of small blood vessels,  usually veins and venules (Figs.  1 to 4). The 
inflammatory cells were predominantly mononuclear in type; polymorphonu- 
clear leukocytes and plasma cells were present in very small numbers (Fig. 5). 
Vascular lesions were almost always confined to white matter and were particu- 
larly prone to occur beneath the ependymal lining of the lateral ventricles,  in 
the  dorsal  portion  of the mesencephalon,  and  below the floor  of the fourth 
ventricle. Spinal cord lesions were present only in those 2 recipients displaying 
clinical signs (Fig. 6). Perivascular demyelination of any significant  degree was 
not found. Astrocyte proliferation was either minimal or not present. Neurons, 
axons, and other cellular  elements of the parenchymal nervous tissue showed 
no conspicuous histological  alterations. Sparse, focal collections of mononuclear 
cells were occasionally present in the leptomeninges,  usually oriented around 
a  vessel,  and were always accompanied by 1 or more vascular lesions  in the 
immediately underlying nervous tissue.  The morphology and  distribution  of 
the CNS lesions in recipients were indistinguishable from the AE lesions induced 
actively in rats by injection of nervous tissue adjuvant. The recipient lesions 
differed only by being usually less intense and less numerous. 
Non-neural tissues (liver, spleen, kidneys, and cervical-axillary lymph nodes) 
were collected from 6 recipient rats with CNS lesions. These tissues revealed 
neither gross nor microscopic  histological  changes of significance.  In addition, 
brains,  spinal  cords,  thyroid,  heart,  lungs,  livers,  spleens,  kidneys, adrenals, 
testis, and lymph nodes were obtained from 24 rats injected neonatally with 
comparable numbers of normal rat spleen cells and sacrificed 5 to 7 weeks later 
without receiving donor lymph node cells. These tissues showed no conspicuous 
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Additional lymph node cell  transfers  were performed  using  recipients  pre- 
treated neonatally with spleen cells from rats other than those providing the trans- 
[erred lyrapk cells. The results of 10 transfers of this  type are shown in Table 
III. A total of 6 of 29recipients had AE lesions. These 6 positive recipients were 
confined to transfers 17, 18, and 19 and received 68, 83, and 118 million lymph 
TABLE III 
Allergic, Encephalomyditis (AE) in Recipient Rats after  Transfer of Lymph Node Cells 
Donor rats providing  lymph node cells injected  with spinal  Cord-adjuvant.  Recipients 
pre-treated  neonatall,' with normal spleen cells from rats other than these donor rats (see text), 
Fotal.. 
Transfer No.* 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
No. of donor 
rats* 
34 
"i 
No. of donor 
lymph node cells 
transferred (X 10s) 
33 
41 
43 
68 
83 
118 
118 
138 
? 
? 
Recipient rats~ 
No.  of rats 
29 
Days after 
transfer 
sacrifice 
Occt.zrrence of 
AE lesions 
0/4§ 
0/3 
0/3 
2/2 
3/3 
1/2 
o/1 
o/7 
0/1 
o/3 
6/29 
? Clumping precluded accurate  count; probably more than 100 X  10  a cell transferred. 
* Donors in transfers  18 and  19 sacrificed 12 daYs after injection; 3 of these 6 donors ex- 
hibited  paralysis on day sacrificed and had AE lesions, as did 1 of the 3 remaining donors. 
The 28 donors in the other transfers  were sacrificed 7 days after injection;  none showed 
clinical disease and only 1 of 20 examined histologically had AE lesions. 
Recipients pretreated  with from 14 to 25 million viable spleen cells when 1 to 3 days 
old except those used in transfers  14 and 21 which were pretreated  when 4 and 7 days old, 
respectively. Lymph node cells transferred  to recipients 5 to 6 weeks after pretreatment. 
§ Numerator, No. of recipients  with AE lesions; denominator,  No. of recipients used in 
transfer. 
node cells, respectively. Four of these 6 recipients (transfers 18 and I9) received 
lymph node cells collected from donors 12 days after injection, at which time 
3  of the 6 donors showed hindleg paralysis. Three of the 6 positive' recipients 
(2 in transfer  18 and 1 in transfer  17) displayed ataxia and hindleg weakness 
2, 4,  and 5  days after  cell transfer,  respectively.  The clinical  signs were Still 
present  when the animals were sacrificed 2 to 6  days later.  These 3 rats with 
clinical  evidence  of  disease  were  subsequently  found  to  have  particularly 128  TRANSFER  O~'  ALLERGIC  ENCEPHALOMYELITIS 
striking AE lesions in their brains and spinal cords.  The CNS lesions present 
in all 6 positive recipients had all the features described above. Microscopic 
examination of sections of kidneys, spleen,  liver,  and lymph nodes  from 2 of 
these 6 positive recipients revealed no important histological  alterations. 
TABLE  IV 
Lymph NodeC~Transf~slnvol~ngC~trol-DonorandC~trol-R~ipirntRats 
Fransfer no. 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
Fotal  42 
No. 
of 
rats 
4 
4 
4 
Donor rats 
Iaj. with* 
Kidney 
4¢ 
¢¢ 
4¢ 
¢¢ 
4¢ 
Kidney 
¢¢ 
4¢ 
4¢ 
Spinal cord 
4,  44 
t¢  4¢ 
Not injected 
44  44 
No. of donor 
lymph node 
cells trans- 
ferred~ 
(X lo  6) 
41 
43 
52 
54 
56 
59 
135 
180 
187 
244 
49 
118 
130 
50 
74 
No 
of 
rat 
26 
Recipient rats§ 
Pre-treated neonatally with 
Spleen cells of donors 
4¢  44  4¢  4¢ 
¢4  ¢C  4¢  t¢ 
~4  ¢4  ~4  4~ 
~4  44  4¢  44 
~4  ¢4  44  4¢ 
Spleen  cells of  rats  other 
than donors 
~4 
4¢ 
44 
Not pretreated 
~¢  44 
I¢  4¢ 
Spleen cells of donors 
O¢~llr- 
r~l~ 
of AE 
lesions 
o/111 
0/1 
0/1 
0/1 
0/1 
0/I 
0/2 
"  0/2 
0/2 
0/2 
0/2 
0/2 
o/4 
0/2 
0/2 
0/26 
* Indicated tissue emulsified  in adjuvant (see  text). 
:~ Indicated No. of viable donor lymph node cells collected 7 or 12 days after injection. 
§ Littermates of recipients used in other transfers (Tables II and III) and pretreated as 
described; sacrificed 6, 7 or 8 days after lymph node cell transfers and examined for lesions 
of allergic encephalomyelitis (AE). 
II Numerator, No. of recipients with AE lesions; No. of recipients in each group. 
Of the 7 unsuccessful transfers shown in Table III Nos. 14, 15, 16, and 20 
were technically satisfactory and consisted respectively of 33, 41, 43, and 118 
million  lymph  node  cells  collected from  donors  7 days after  injection.  The 
remaining  3  unsuccessful  transfers  were  not  satisfactory  from  a  technical 
standpoint.  In 1 of them (No. 21) a very low donor:recipient ratio was used P.  Y.  PATERSON  129 
and in the other 2 (Nos. 22 and 23) the donor cell preparations showed exten- 
sive clumping. 
Lymph Node Cell Transfers Involving Control-Donors and Control-Recipients. 
--Donors  were  injected with kidney emulsified  in  complete  adjuvant.  Re- 
cipients were pretreated neonatally with normal spleen cells from either these 
same donors  or from rats other than those providing the lymph node cells 
transferred. In addition, lymph node cells from uninjected donors were trans- 
ferred to spleen cell pretreated recipients  and lymph node cells from spinal 
cord-adjuvant donors were transferred to recipients not pretreated neonatally. 
The results of these transfers are shown in Table IV. None of the 26 recipients 
exhibited clinical signs and none were found to have CNS lesions when sacrificed 
6 to 8 days after transfer of 41 to 244 million donor lymph node cells. 
Antibodies against Nervoua Tissue in Sera of Recipient Rats.--It was expected 
that  lymph node cells collected  from donor rats  injected with  spinal  cord 
adjuvant would elaborate complement-fixing (CF) antibodies against nervous 
tissue for varying periods of time after their transfer to recipient  rats. It was 
assumed that the levels of CF antibodies demonstrable in recipient sera would 
provide information as to how well the transferred donor cells survived and 
functioned in the recipients.  For this reason quantitative CF tests were set up 
using sera  obtained from recipients  6 to 8 days after transfer and rat brain 
antigen. Preliminary tests showed that sera from normal rats or rats injected 
with guinea pig kidney in adjuvant tested against rat brain antigen fixed less 
than 6 C~H60, in most instances less than 3 C~Hs0, of exactly 100 CrH60 avail- 
able. Fixation of more than 6 C~Hs0 was considered, therefore,  to indicate the 
presence  of CF antibodies against brain. 
Representative results of CF tests are shown in Table V.  Eight recipients 
were pretreated with spleen cells; 4 recipients  were not pretreated. All 12 ani- 
mals received  approximately the same  number of viable  donor lymph node 
cells. CF antibodies against brain were present in sera from 4 of the 5 recipients 
pretreated with spleen cells from the prospective lymph node cell donors; these 
4 sera fixed from 9 to 19 CtHs0. CF antibodies were also present in serum of 
1 of the 3 recipients pretreated with spleen cells from rats other than the lymph 
cell donors;  this serum fixed 10 CrH60. In contrast, none of the sera from the 
4 recipients, which were not pretreated with spleen cells, had appreciable levels 
of antibodies; all 4 sera fixed less than 6 C'Hs0. CF tests with sera from 25 addi- 
tional recipient  rats gave comparable  results. 
Judging from the levels of antibodies present in recipients  of lymph node 
cells, it was  apparent  that donor cells survived and continued to elaborate 
antibodies for appreciable  periods  only in  those  recipients  pretreated  with 
spleen cells from the prospective lymph node cell donors. Most of the sera from 
such recipients  contained circulating  antibodies  against brain, fixing from 6 to 
22 C'Hs0. As anticipated, there was no direct relationship between the presence 130  TRANS~FER O~F ALLERGIC ENCEPHALOMYELITIS 
of CF  antibodies  and  the  occurrence of AE lesions  in  these  individual  rats. 
Previous  studies  (2,  8)  showed  that  these  CF  antibodies,  directed  against 
alcohol soluble and non-paralytogenic, nervous tissue antigen(s), probably play 
no direct role in initiating AE. Only a few of the sera from recipients pretreated 
with spleen cells from rats other than those used as donors of lymph node cells 
contained antibodies.  Sera from these few animals fixed from 7 to 11  C'H60. 
TABLE V 
Fixation of Guinea Pig Complement  by Sera of Recipient Rats, after lymph Node Cell 
Transfers,  and Rat Brain Anti  en 
No. of donor lymph  No. of C'H6, 
Recipient  Neonatal pretreatment of recipients*  node cells trans-  fixed  with rat  rat .No.  ferred$ (X 10  e)  brain  antigen§ 
32  9  C-775 
C-776 
C-780 
C-781 
C-782 
C-783 
C-784 
C-785 
C-768 
C-769 
C-770 
C-771 
Normal spleen cells of prospective  lymph 
node cell donors 
~¢  ~c 
Normal spleen cells of rats other than lymph 
32 
37 
37 
37 
43 
node cell donors 
None 
¢¢ 
"  43 
"  43 
49 
49 
118 
118 
1 
19 
10 
12 
10 
5 
* Rats injected 1 to 3 days after birth with from 17 to 28 million spleen cells of indicated 
donor rats. 
Lymph node cells collected from donors 7 days after injection of spinal cord adjuvant 
and transferred to recipients 5 to 6 weeks old. 
§ Maximum No. of 50 per cent hemolytic units of complement (C'Hn0) fixed, of 100 C'H60 
available,  by 0.25 ml. serum in presence of rat brain  antigen  diluted  1:250 or 1:1000. All 
sera collected from recipients 6 or 8 days after lymph cell transfers. 
DISCUSSION 
The results of this study (Tables II and III) indicate that cellular transfer 
of AE can be accomplished by injection of lymph node cells from spinal cord- 
injected  donor rats  into recipient  rats pretreated  neonatally with  normal  rat 
spleen cells. Transfer can be accomplished frequently if the recipients are pre- 
treated with spleen  cells of the prospective lymph node cell donors. Transfer 
is achieved occasionally if the recipients are pretreated  with spleen cells from 
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The CNS lesions in positive recipients are indistinguishable from acute AE 
lesions found in rats injected with spinal cord adjuvant. Three lines of evidence 
support the conclusion  that the recipient CNS lesions are the result of passive, 
rather than active, "sensitization" to spinal cord antigen(s). First, CNS lesions 
were present in recipients sacrificed 6 to 8 days after cell transfer. Previous work 
(14, 38) has shown that rats actively sensitized  to nervous tissue rarely have 
demonstrable lesions until 9 days after injection. And in this study, only 2 of 
45 donors (Tables II, III, and IV) sacrificed 7 days after injection and examined 
histologically had  demonstrable AE lesions.  Second,  5 of the 20 positive re- 
cipients (Tables II and III) displayed clinical signs of AE as soon as 2 to 5 days 
after cell transfer. Other studies (1, 2, 10, 14, 38 and Table I) have established 
that clinical signs rarely appear in actively sensitized  rats until 10 days follow- 
ing injection. Third, the donor lymph node cells were transferred to recipients 
via the intravenous route. This particular route of injection, in our hands, has 
proven ineffective for induction of AE in rats using spinal cord emulsions. 
The  transfers  of AE  described here  can  best be attributed  to  the use of 
recipients which had acquired immunological  tolerance of donor lymph node 
cells,  to a  varying degree,  as a  result of neonatal pretreatment  with pooled, 
viable, normal rat spleen  cells. The recipients were deliberately pretreated at 
an age and in a manner shown by several workers (19-22) to induce homograft 
tolerance in rats. More recently, Ashley et a/. (39, 40) have found that newborn 
rats injected with pooled blood from a group of adult donor rats may later be 
tolerant of skin grafts from these same donors as well as other rats outside the 
donor group. Terasaki, Cannon, and Longmire (41, 42), and Ha~ek and Hagkov~ 
(43) have obtained comparable results with chickens and ducks. These various 
studies indicate that by using pooled donor cells it is possible not only to simul- 
taneously induce tolerance to skin grafts from more than  1 donor animal but 
also induce some degree of tolerance to skin  transplants from  other  unrelated 
donors as well. This latter finding may be explained,  particularly in the case of 
rats,  by long  term  closed colony breeding  with  resultant  sharing  of strong 
histocompatibility genes by different animals  (44).  Although we did not test 
our  pretreated  recipient  rats  for homograft  tolerance  by skin  grafting,  the 
serological  tests (Table V) provided indirect evidence that the recipients had 
less capacity to reject transferred donor lymph cells. Donor lymph node cells 
survived and produced antibodies against brain antigen(s)  much better after 
transfer to spleen cell pretreated, in contrast to normal,  recipient rats. This was 
particularly  true when the spleen cells used for pretreatment  were from the 
same donors providing the transferred lymph node cells, under the conditions 
that cellular  transfer of AE was most often accomplished. 
In  contrast,  attempts  to  transfer  the  disease in  a  comparable manner  to 
recipients which were not pretreated failed (Table IV). This finding confirmed 
many previous transfer attempts of this type made in this laboratory with both 132  TRANSFER  0]~ ALLERGIC  ENCEPHALOMYELITIS 
rats and guinea pigs. While it may well be possible to accomplish cellular trans- 
fer of AE using normal, genetically dissimilar, rats or other species of animals, 
the conditions for such transfer remain to be defined. Our data indicate that 
spleen cell pretreatment facilitates ceUular transfer of the disease in the rat. 
Extended  survival  of  functioning  donor  cells,  relatively  unmolested  by 
immunological attack by the recipient, may well be an important factor in AE 
transfers.  Under such circumstances, the transferred ceUs themselves and/or 
antibodies elaborated by them would have a better opportunity to react with 
antigen(s) in the CNS of the recipient. 
This concept of extended survival of donor cells is  supported by the results of 
recent AE transfer attempts of other workers./~strom and Waksman (45) have found 
AE-like  lesions  in  heavily x-irradiated recipient rabbits within  10 days  after in- 
travenous injection of large numbers of lymph node cells from spinal  cord-injected 
donors. These workers have described an experiment involving  1 recipient in detail 
(46). Leonard and Thomas (47) have suggestive evidence that AE may be transferred 
to normal guinea pigs if the donor cells are injected v/a the intracerebral route. In 
both of these studies,  the cells were transferred to an environment in which  they 
could survive and function for appreciable  periods of time. 
While Lipton and Freund (14) have shown that AE in the rat can be transferred 
by parabiosis,  our transfer studies  indicate  that a  factor(s)  intimately associated 
with washed, viable, lymph node cells of rats injected with nervous tissue adjuvant 
is capable of causing AE in recipients.  The data do not indicate whether the tissue 
damage recognized as AE is initiated by antibodies  released by these cells after their 
transfer or by the transferred ceils themselves. 
The relative importance of an immune factor(s) associated with living ceils 
and conventional circulating antibodies in the production of this disease, thus, 
remains to be elucidated. The transfers reported here do provide direct evi- 
dence that allergic encephalomyelitis has an immunological mechanism.  The 
transfers provide additional means for defining the sequence of events responsi- 
ble for this disease in more precise terms. 
SI3"M~.4R¥ 
Transfer of allergic encephalomyelitis has  been accomplished by injection 
of lymph node ceils,  obtained from donor rats sensitized to spinal cord, into 
recipient rats pretreated neonatally with normal rat spleen cells.  Transfer of 
the disease may be achieved most frequently when the recipients are pretreated 
with spleen cells of the prospective lymph node cell donors. These transfers are 
attributed to the use of recipients which have acquired immunological tolerance 
to donor lymph node ceils,  as a  result of the spleen cell pretreatment, and in 
which, therefore, the donor ceils can survive and function longer after transfer. 
The author is indebted to Dr. Lewis Thomas for his helpful suggestions concerning the 
initial phases of this work. The technical services of Mr. Norman Didakow were invaluable P.  Y.  PATERSON  133 
throughout the entire study. Dr. Quentin N.  Myrvik kindly maintained and supplied in 
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EXPLANATION OF PLATES 
PLATE 3 
FIo.  1.  Recipient  rat  C830. Animal  exhibited  severe  ataxia-hindleg  weakness 
5 days after transfer  of donor lymph node cells; sacrificed ? days after cell transfer. 
Two  vascular-perivascular  inflammatory  lesions in  mesencephalon.  Hematoxylin 
and eosin. ×  130. 
FIG. 2.  Recipient  rat C839. No clinical signs; sacrificed 8 days after transfer  of 
donor lymph node cells. Vascular lesion in cerebellum. Hematoxylin and eosin. ×  130 THE  JOURNAL  OF  EXPERIMENTAL  MEDICINE  VOL.  111  PLATE  3 
(Paterson: Transfer of allergic encephalomyelitis) PLATE  4 
FIG.  3.  Recipient  rat  C836.  Displayed  severe  ataxia-hindleg weakness  4  days 
after transfer of donor lymph node cells; sacrificed 8 days after transfer of cells. Two 
vascular lesions adjacent to  ependymal lining of lateral ventricle. Hematoxylin and 
eosin.  ×  130. 
FIG. 4.  Recipient rat C415.  Sacrificed 6 days after transfer of donor lymph node 
cells without  displaying clinical signs.  Vascular lesions in  pons.  Hematoxylin and 
eosin.  X  125. THE  JOURNAL  OF  EXPERIMENTAL  MEDICINE  VOL.  111  PLATE  4 
(Paterson: Transfer of allergic encephalomyelitis) PLATE  5 
FIG. 5.  Recipient rat  C412.  Sacrificed 6  days after cell transfer.  Vascular lesion 
in pons. Hematoxylin and eosin.  X  500. THE  JOURNAL  OF  EXPERIMENTAL  MEDICINE  VOL.  1ll  PLATE  5 
(Paterson: Transfer of allergic encephalomyelitis) PLATE  6 
FIG. 6.  Recipient rat  C836.  Appearance of hindleg weakness 4  days after donor 
lymph node cell transfer, Three lesions in longitudinal section of spinal cord. Hema- 
toxylin and eosin.  X  130. THE  JOURNAL  OF  EXPERIMENTAL  MEDICINE  VOL.  111  PLATE  6 
(Paterson: Transfer of allergic encephalomyelitis) 